Unfortunately the NHP results only relate to safety - nothing to do with efficacy or SVR. I have not seen or heard any statement that confirms that the trial dosing levels produce the same results as the doses in the replicon model and it this this piece of infromation that we need if there is to be no published SVR data. If David confirms that the replicon results are being mirrored in the trial, then that would satisfy my interest.
- Forums
- ASX - By Stock
- BLT
- Ann: Chairman's Address to Shareholders
Ann: Chairman's Address to Shareholders, page-40
-
Share
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BLT (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online